XML 116 R11.htm IDEA: XBRL DOCUMENT
v3.20.1

Revenues Revenues | 3 Months Ended
--- | ---
Mar. 31, 2020
Revenue from Contract with Customer [Abstract] |
Revenues | Revenues Product Revenues Revenues by product are summarized as follows:
|  | For the Three Months Ended March 31,
(In millions) |  | 2020 |  | 2019
|  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |  |
Fumarate* |  | $ | 777.5 |  |  | $ | 323.3 |  |  | $ | 1,100.8 |  |  | $ | 717.7 |  |  | $ | 281.1 |  |  | $ | 998.8 |
Interferon** |  | 292.6 |  |  | 173.4 |  |  | 466.0 |  |  | 327.3 |  |  | 173.6 |  |  | 500.9 |
TYSABRI |  | 277.7 |  |  | 244.7 |  |  | 522.4 |  |  | 245.0 |  |  | 215.4 |  |  | 460.4 |
FAMPYRA |  | — |  |  | 28.3 |  |  | 28.3 |  |  | — |  |  | 22.9 |  |  | 22.9 |
Subtotal: MS product revenues |  | 1,347.8 |  |  | 769.7 |  |  | 2,117.5 |  |  | 1,290.0 |  |  | 693.0 |  |  | 1,983.0 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA |  | 235.4 |  |  | 329.6 |  |  | 565.0 |  |  | 223.3 |  |  | 295.2 |  |  | 518.5 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |  |
BENEPALI |  | — |  |  | 133.5 |  |  | 133.5 |  |  | — |  |  | 124.0 |  |  | 124.0 |
IMRALDI |  | — |  |  | 61.6 |  |  | 61.6 |  |  | — |  |  | 35.7 |  |  | 35.7 |
FLIXABI |  | — |  |  | 23.7 |  |  | 23.7 |  |  | — |  |  | 14.7 |  |  | 14.7 |
Subtotal: Biosimilar product revenues |  | — |  |  | 218.8 |  |  | 218.8 |  |  | — |  |  | 174.4 |  |  | 174.4 |
Other: |  |  |  |  |  |  |  |  |  |  |  |
FUMADERM |  | — |  |  | 3.3 |  |  | 3.3 |  |  | — |  |  | 4.1 |  |  | 4.1 |
Total product revenues |  | $ | 1,583.2 |  |  | $ | 1,321.4 |  |  | $ | 2,904.6 |  |  | $ | 1,513.3 |  |  | $ | 1,166.7 |  |  | $ | 2,680.0 |
*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became available in the U.S. in November 2019. **Interferon includes AVONEX and PLEGRIDY. We recognized revenues from two wholesalers accounting for 30.0% and 14.6% of gross product revenues for the three months ended March 31, 2020, and 31.3% and 14.2% for the three months ended March 31, 2019. An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) |  | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Balance, as of December 31, 2019 |  | $ | 131.1 |  |  | $ | 1,027.3 |  |  | $ | 40.5 |  |  | $ | 1,198.9 |
Current provisions relating to sales in current year |  | 200.7 |  |  | 827.9 |  |  | 4.7 |  |  | 1,033.3 |
Adjustments relating to prior years |  | (0.5 | ) |  | (15.9 | ) |  | (0.5 | ) |  | (16.9 | )
Payments/credits relating to sales in current year |  | (73.4 | ) |  | (310.3 | ) |  | — |  |  | (383.7 | )
Payments/credits relating to sales in prior years |  | (112.2 | ) |  | (432.8 | ) |  | (4.8 | ) |  | (549.8 | )
Balance, as of March 31, 2020 |  | $ | 145.7 |  |  | $ | 1,096.2 |  |  | $ | 39.9 |  |  | $ | 1,281.8 |
The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions) |  | As of March 31, 2020 |  | As of December 31, 2019
Reduction of accounts receivable, net |  | $ | 235.4 |  |  | $ | 197.8 |
Component of accrued expenses and other |  | 1,046.4 |  |  | 1,001.1 |
Total revenue-related reserves |  | $ | 1,281.8 |  |  | $ | 1,198.9 |
Revenues from Anti-CD20 Therapeutic Programs Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
|  | For the Three Months Ended March 31,
(In millions) |  | 2020 |  | 2019
Biogen’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA |  | $ | 341.3 |  |  | $ | 390.8 |
Other revenues from anti-CD20 therapeutic programs |  | 179.1 |  |  | 126.6 |
Total revenues from anti-CD20 therapeutic programs |  | $ | 520.4 |  |  | $ | 517.4 |
For additional information on our collaboration arrangements with Genentech, please read Note 18, Collaborative and Other Relationships, to our consolidated financial statements included in our 2019 Form 10-K. Other Revenues Other revenues are summarized as follows:
|  | For the Three Months Ended March 31,
(In millions) |  | 2020 |  | 2019
Revenues from collaborative and other relationships: |  |  |  |
Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis |  | $ | 3.7 |  |  | $ | 24.8 |
Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc. |  | 0.2 |  |  | (0.4 | )
Other royalty and corporate revenues: |  |  |  |
Royalty |  | 11.4 |  |  | 3.9 |
Other corporate |  | 94.0 |  |  | 264.1 |
Total other revenues |  | $ | 109.3 |  |  | $ | 292.4 |
Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the three months ended March 31, 2019, we recognized $206.8 million in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business. During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we license certain of our manufacturing-related intellectual property to the customer. We are eligible to receive up to $500.0 million in a series of three payments. The first payment is due upon a regulatory achievement related to the customer’s product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We expect the regulatory achievement to occur in 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration